Bruce L. Miller

4 ta ish

University of California, San Francisco

1. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

   Raymond Scott Turner, Ronald G. Thomas, Suzanne Craft +39

   Maqola20152 iqtibos

   ABIABI:AkademIndex/2026.other.267435

2. Reduction of β‐amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease

   Ruth Motter, Carmen Vigo‐Pelfrey, Dora Kholodenko +14

   Maqola19952 iqtibos

   ABIABI:AkademIndex/2026.other.775789

3. The Nairobi Declaration—Reducing the burden of dementia in low‐ and middle‐income countries (LMICs): Declaration of the 2022 Symposium on Dementia and Brain Aging in LMICs

   Gladys E. Maestre, Maria Carrillo, Raj N. Kalaria +97

   MaqolaOAOchiq kirishAging, Elder Care, and Social IssuesAlzheimer s & Dementia20231 iqtibos

   ABIABI:AkademIndex/2026.other.038005

4. The 2022 symposium on dementia and brain aging in low‐ and middle‐income countries: Highlights on research, diagnosis, care, and impact

   Raj N. Kalaria, Gladys E. Maestre, Simin Mahinrad +79

   Sharh maqolaOAOchiq kirishDementia and Cognitive Impairment ResearchAlzheimer s & Dementia20240 iqtibos

   ABIABI:AkademIndex/2024.review-article.000002